NASDAQConsumer StaplesAgricultural InputsSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-12-30 | ||
| Revenue | — | 1.8M |
| EPS | — | -0.6 |
| Annual ending 2026-12-31 | ||
| Revenue | — | 7.7M |
| EPS | — | -2.42 |
Management figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Use capital to support growth and shareholder value | A supporting condition in ARCADIA BIOSCIENCES INC's published investment case. The stated target is Effective use of $4 million capital to support growth by end 2026. | Under Pressure | Capital raised is not used effectively to support growth | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce net losses to improve financial health | These steps could help fix losses and improve value. | Broken | Net loss worsens beyond -$4.4 million next quarters | Net income: $-6.266M FY2026-Q2; GAAP. Published target: Net loss improves toward -$1.3 million or better by 2026-Q4. The stored target says 2026-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 13, 2026-6,266,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: cb330694-409c-4bc2-a208-c6b50ed7418c. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to support financial improvement | A primary condition in ARCADIA BIOSCIENCES INC's published investment case. The stated target is >= $1.1 million next quarter. | Intact | Revenue falls below $1.1 million next quarter | Revenue: $1.443M FY2026-Q2; GAAP. Published target: >= $1.1 million next quarter. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 13, 20261,443,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: cb330694-409c-4bc2-a208-c6b50ed7418c. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making growth story rather than an established compounder. The long-term thesis is in a watch state: Zola initiatives are progressing, but recent performance is weak and management execution is mixed.
RKDA is tagged as cheap versus peers, while the expectations gap is negative, suggesting current expectations may still be demanding relative to the evidence. Confidence in that valuation read is low, and the snapshot does not indicate concentrated fragility in what is priced in.
Near term, the risk of an earnings miss is elevated, and recent performance is well below the industry cohort. Zola sales and planned launches show progress, while cost reductions and the June funding raise support execution; however, the cost-control priority is marked behind, and recent delisting-rule notices add risk.
Over the next few quarters, the thesis depends on Zola growth continuing through new product launches and on RKDA managing inventory, shipping, and working-capital needs. A guidance cut or weaker employment data would add pressure, while stronger results and guidance from major consumer-staples companies could support the sector backdrop.
For the 1-to-3-year view, RKDA has signs of brand growth but remains a fragile, loss-making business with volatile management signals and substantial near-term risk. The thesis hinges on sustained execution and progress on listing concerns. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.